IL-2 and Mycobacterial Lipoarabinomannan as Targets of Immune Responses in Multiple Sclerosis Patients.

HERV-W IL-2 Mycobacterium avium subsp. paratuberculosis antibodies autoimmune response interleukin 2 multiple sclerosis

Journal

Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893

Informations de publication

Date de publication:
01 Apr 2020
Historique:
received: 18 02 2020
revised: 27 03 2020
accepted: 27 03 2020
entrez: 5 4 2020
pubmed: 5 4 2020
medline: 5 4 2020
Statut: epublish

Résumé

Interleukin 2 (IL-2) is considered a key player in exacerbating multiple sclerosis (MS). Therapies targeting its receptor have been developed; however, a resolution of the disease and side effects are still an issue of concern. The involvement of other factors, such as

Identifiants

pubmed: 32244639
pii: microorganisms8040500
doi: 10.3390/microorganisms8040500
pmc: PMC7232413
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Pediatr Diabetes. 2015 May;16(3):189-95
pubmed: 25720593
Biomedicines. 2019 Mar 11;7(1):
pubmed: 30862055
Expert Rev Clin Pharmacol. 2014 Jan;7(1):9-19
pubmed: 24308792
J Neurol Sci. 2015 Oct 15;357(1-2):106-8
pubmed: 26190523
Mult Scler. 2019 Oct;25(12):1618-1632
pubmed: 30657420
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):339-40
pubmed: 21429904
Br Med J. 1939 May 20;1(4089):1024-1046.3
pubmed: 20782357
Ther Adv Neurol Disord. 2016 May;9(3):211-5
pubmed: 27134676
Front Microbiol. 2018 Mar 14;9:462
pubmed: 29593697
Anim Biotechnol. 2013;24(3):187-97
pubmed: 23777348
J Neuroimmunol. 2014 May 15;270(1-2):51-5
pubmed: 24642384
J Neuroimmunol. 2020 Jan 15;338:577110
pubmed: 31715457
Proc Natl Acad Sci U S A. 2019 Oct 15;116(42):21120-21130
pubmed: 31570576
Mult Scler. 2011 Nov;17(11):1282-9
pubmed: 21652610
J Exp Med. 2008 Aug 4;205(8):1763-73
pubmed: 18663124
Int J Infect Dis. 2009 Sep;13(5):e254-63
pubmed: 19303801
J Neuroimmunol. 2016 Feb 15;291:29-38
pubmed: 26857492
Clin Rev Allergy Immunol. 2010 Aug;39(1):51-61
pubmed: 19697163
Cells. 2019 Jun 04;8(6):
pubmed: 31167379
BMC Neurol. 2016 Aug 23;16(1):148
pubmed: 27552900
Expert Rev Neurother. 2013 Dec;13(12 Suppl):3-9
pubmed: 24289836
Ther Adv Neurol Disord. 2017 Jan;10(1):67-75
pubmed: 28450896
PLoS One. 2013 Dec 06;8(12):e80128
pubmed: 24324591
BMC Immunol. 2018 Nov 8;19(1):33
pubmed: 30409122
Nat Commun. 2016 Oct 06;7:13027
pubmed: 27708334
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
J Clin Neurosci. 2014 Jan;21(1):12-21
pubmed: 23916471
Vet Microbiol. 2000 Dec 20;77(3-4):465-73
pubmed: 11118731
Int Rev Immunol. 2010 Aug;29(4):351-70
pubmed: 20635879
Ther Adv Neurol Disord. 2017 Jul;10(7):265-289
pubmed: 28670343

Auteurs

Marco Bo (M)

Department of Biomedical Sciences, Division of Microbiology and Virology, University of Sassari, 07100 Sassari, Italy.

Magdalena Niegowska (M)

Department of Biomedical Sciences, Division of Microbiology and Virology, University of Sassari, 07100 Sassari, Italy.

Jessica Frau (J)

Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna, Department of Medical Sciences and Public Health, University of Cagliari, 09126 Cagliari, Italy.

GianPietro Sechi (G)

Clinic of Neurology, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.

Giannina Arru (G)

Clinic of Neurology, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.

Eleonora Cocco (E)

Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna, Department of Medical Sciences and Public Health, University of Cagliari, 09126 Cagliari, Italy.

Leonardo A Sechi (LA)

Department of Biomedical Sciences, Division of Microbiology and Virology, University of Sassari, 07100 Sassari, Italy.

Classifications MeSH